Durability of therapeutic response with long-term aripiprazole lauroxil treatment following successful resolution of an acute episode of Schizophrenia

Joseph P. McEvoy, Robert Risinger, Serhiy Mykhnyak, Yangchun Du, Chih Chin Liu, Arielle D. Stanford, Peter J. Weiden

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

Objective: To evaluate durability of therapeutic effect of long-term treatment with aripiprazole lauroxil in patients with schizophrenia following successful treatment of an acute psychotic episode. Methods: This post hoc analysis assessed long-term outcomes for a subgroup of patients who entered a 52-week extension study after being successfully stabilized with one of 2 doses of aripiprazole lauroxil (441 or 882 mg) in a pivotal 12-week, placebo-controlled, randomized clinical trial. Durability of therapeutic effect was measured by the proportion of patients completing the 1-year course of aripiprazole lauroxil, the trajectories of the Positive and Negative Syndrome Scale (PANSS) total and the Clinical Global Impression-Severity (CGI-S) item scores beyond the first 12 weeks, and the likelihood of remission at any follow-up point. Results: In total, 181 patients treated with aripiprazole lauroxil entered the extension study; 73% and 66% of patients from the 441 mg and 882 mg groups, respectively, completed all 13 aripiprazole lauroxil treatments scheduled every 4 weeks over 52 weeks. Both groups continued on a positive trajectory of symptom improvements (P <.0001 for reductions in PANSS total and CGI-S scores from week 12 to end of follow-up). Most patients (74% and 68% in the aripiprazole lauroxil 441 mg and 882 mg groups, respectively) achieved remission during follow-up. Conclusions: These post hoc analyses of a subgroup of patients demonstrate the continued therapeutic efficacy of aripiprazole lauroxil after successful treatment of an acute episode of schizophrenia. Both the 441 mg and 882 mg groups had similar retention rates, degree of symptom improvement, and likelihood of remission.

Original languageEnglish (US)
Pages (from-to)1103-1109
Number of pages7
JournalJournal of Clinical Psychiatry
Volume78
Issue number8
DOIs
StatePublished - Sep 1 2017

ASJC Scopus subject areas

  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Durability of therapeutic response with long-term aripiprazole lauroxil treatment following successful resolution of an acute episode of Schizophrenia'. Together they form a unique fingerprint.

  • Cite this